Product Description
a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) for the treatment of patients with moderately severe to severe nonproliferative diabetic retinopathy. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04782128)
Mechanisms of Action: VEGF Blocker, FGFR2 Blocker
Novel Mechanism: Yes
Modality: Fusion Protein
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Rongchang Biopharmaceuticals (Yantai) Co., Ltd.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Macular Edema|Wet Macular Degeneration
Phase 2: Diabetic Retinopathy
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20202586 |
CTR20202586 | P2 |
Completed |
Diabetic Retinopathy |
2024-07-05 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT05885503 |
28C005 | P3 |
Recruiting |
Macular Edema |
2026-06-01 |
11% |
2023-09-06 |
|
CTR20230065 |
CTR20230065 | P3 |
Completed |
Wet Macular Degeneration |
2025-11-13 |
2025-12-14 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/26/2025 |
News Article |
Prince Silver Provides Update on 2025 Drilling Program at the Prince Project, Nevada |
|
08/18/2025 |
News Article |
RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries |
|
06/05/2023 |
News Article |
RemeGen Demonstrates Profitability to Successfully Receive Approval from the Hong Kong Stock Exchange to Upgrade Stock Short Name |
|
08/05/2021 |
News Article |
Diabetic Retinopathy Drug Pipeline Research Report 2021 - ResearchAndMarkets.com |